GlassScriptPhysician profile
Blake Matherne
NPI 1265933626
$4,568.29
in general payments reported to CMS, 2019-2025
16 companies · $1,156 in 2025
The $1,156 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2021: $290 · 2022: $989 · 2023: $1,102 · 2024: $831 · 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950 · Long Term Medical Supply Or Device Loan: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,949.97 |
| Long Term Medical Supply Or Device Loan | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $945.02 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $838.23 | 2022-2025 | Catalys System, Tecnis Iol, Tecnis Iol |
| Alcon Vision LLC | $673.74 | 2021-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Sight Sciences, INC. | $496.08 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $409.12 | 2022-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Allergan, INC. | $297.05 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $255.67 | 2023-2024 | Omidria, Rayone Spheric, Rayone Emv |
| Ocular Therapeutix, INC. | $164.66 | 2023 | Dextenza |
| Oyster Point Pharma, INC. | $117.92 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $111.89 | 2023 | Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.05 | 2019 | |
| Dompe US, INC. | $64.02 | 2025 | Oxervate |
| Harrow Eye, LLC | $36.63 | 2024 | Vevye |
| Biotissue Holdings INC. | $20.86 | 2025 | |
| Amgen INC. | $20.00 | 2025 | Tepezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $18.35 | 2023 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Matherne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.